University of Queensland researchers are one step closer to building new medicines for treating inflammatory diseases, including allergies such as rhinitis, tingling hives, asthma, eczema and dermatitis.
A group from UQ’s Institute for Molecular Bioscience(IMB) and the ARC Centre of Excellence in Advanced Molecular Imaging has built molecular switches that can control a defence response to many common allergens.
UQ IMB researcher Dr Abishek Iyer pronounced tellurian defence cells responded to allergens by releasing histamine and other chemicals that means inflammation and lead to allergic reactions.
“We can take anti-histamines to soothe a symptoms of some allergies, though these medicines don’t impact a base causes of inflammation that can lead to ongoing diseases, including asthma,” Dr Iyer said.
“The molecular switch we have grown turns off an critical protein on a aspect of tellurian defence cells that controls how a defence complement responds to many allergens in a environment.
“This is a new proceed to handling a person’s risk of building serious allergies and inflammatory reactions that lead to disease, though tellurian trials are still some approach off.”
The group also enclosed Dr Rink-Jan Lohman, Dr Robert Reid and Professor David Fairlie, all from the IMB Centre for Inflammation and Disease Research.
Dr Reid pronounced a group built tiny chemical compounds that switched off a duty of a tellurian defence cells that triggered allergic reactions.
Trials of a compounds in tellurian inflammatory cells were found to be effective in treating rodent models of tellurian inflammatory diseases.
The subsequent step is to use a new tiny compounds to improved know a molecular basement of tellurian defence responses and pattern improved treatments for a different operation of allergies, asthma and other inflammatory conditions.
Source: The University of Queensland
Comment this news or article